Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1Dermatologic 1

Conditions

Leukemia, Myeloid, Acute 3Neoplasms 2Plasmacytoma 1Pathologic Complete Response 1Multiple Myeloma 1Lymphoma, T-Cell, Peripheral 1Lymphoma, T-Cell, Cutaneous 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, B-Cell, Marginal Zone 1Leukemia, Large Granular Lymphocytic 1Hepatic Insufficiency 1Hematologic Neoplasms 1Hematologic Diseases 1Colorectal Neoplasms 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Cyclophosphamide 9mogamulizumab 6Biopsy 6fludarabine 5fludarabine phosphate 4Specimen Handling 4Immunoglobulin G 4Disulfides 4Brentuximab Vedotin 4ruxolitinib 3romidepsin 3pembrolizumab 3Peripheral Blood Stem Cell Transplantation 3Mycophenolic Acid 3Magnetic Resonance Spectroscopy 3Lenalidomide 3Etoposide 3Busulfan 3hypericin 2Whole-Body Irradiation 2Vincristine 2Tacrolimus 2Prednisone 2Nivolumab 2Melphalan 2Depsipeptides 2tofacitinib 1thymoglobulin 1tazemetostat 1talimogene laherparepvec 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Lymphoma, T-Cell, Cutaneous × cc-486 × 1 year × Clear all
NCT04447027 2026-01-30

Romidepsin, CC-486 (5-azacitidine), Dexamethasone, and Lenalidomide (RAdR) for Relapsed/Refractory T-cell Malignancies

National Institutes of Health Clinical Center (CC)

Phase 1 Completed
26 enrolled 24 charts
DermatologicLymphoid

Lymphoma, T-Cell, Cutaneous, Lymphoma, T-Cell, Peripheral

Data powered by HemOnc (CC BY 4.0) Colophon âš¡